Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Unicycive Therapeutics, Inc. Common Stock

UNCY

Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.

Last trade $3.72
Day change +$0.02 (+0.54%)
Day range $3.59 – $3.77
Volume 833,362
Market cap $103M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$103.06M
Price / earnings
—
Price / book
1.93×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.78×

Profitability

Earnings per share
-$1.26
Return on assets
-48.9%
Return on equity
-66.12%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.81×
Quick ratio
3.81×
Cash ratio
2.36×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$27.85M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for UNCY, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$7.35M$6.83M$4.97M$4.38M$5.21M$5.82M$3.97M$3.21M
Research and development$2.79M$1.61M$2.25M$2.96M$1.75M$2.17M$5.29M$3.05M
Total operating expenses$10.14M$8.44M$7.22M$7.34M$6.96M$7.99M$9.26M$6.25M
Operating income-$10.14M-$8.44M-$7.22M-$7.34M-$6.96M-$7.99M-$9.26M-$6.25M
Interest expense$0$0-$27K-$15K-$13K-$15K-$20K-$15K
Income before taxes-$1.72M-$12.82M-$14.67M-$6.01M-$6.45M$570K-$21.53M-$4.1M
Income taxes$0$0$0$0$0$0$0$0
Net income-$1.72M-$12.82M-$14.67M-$6.01M-$6.45M$570K-$21.53M-$4.1M
Net income attributable to common shareholders-$1.72M-$12.82M-$14.67M-$6.01M-$6.45M$570K-$21.53M-$4.1M
EBITDA-$10.13M-$8.43M-$7.21M-$7.33M-$6.96M-$7.98M-$9.25M-$6.25M
Basic earnings per share-$0.06-$0.54-$0.68-$0.33-$0.52$0.04-$2.03-$0.46
Diluted earnings per share-$0.06-$0.54-$0.71-$0.33-$0.52-$0.50-$4.30-$0.46

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims Unicycive failed to properly inspect or audit the vendor's facility, creating undisclosed risks of regulatory delays for its oxylanthanum carbonate product. Investors who purchased securities between December 29, 2025 and June 29, 2026 are encouraged to join the case.

GlobeNewswire Inc.

UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role

A class action lawsuit has been filed against Unicycive Therapeutics for allegedly making false and misleading statements regarding its third-party manufacturing vendor. The company allegedly failed to inspect the vendor's facility or audit compliance with manufacturing practices, creating undisclosed risks of FDA delays for oxylanthanum carbonate approval. Investors who purchased shares between December 29, 2025 and June 29, 2026 have until November 2, 2026 to apply as lead plaintiff.

GlobeNewswire Inc.

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims Unicycive failed to properly audit the vendor's facility and lacked reasonable basis for believing deficiencies were remedied, creating material risk of regulatory delays for oxylanthanum carbonate approval. Investors who purchased securities between December 29, 2025 and June 29, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 2, 2026.

GlobeNewswire Inc.

UNCY DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY

Rosen Law Firm issued deadline notices for securities class action lawsuits against Unicycive Therapeutics (UNCY), York Space Systems (YSS), and Papa John's International (PZZA). The UNCY lawsuit alleges the company made false statements about manufacturing compliance and FDA approval prospects for its oxylanthanum carbonate drug. Investors have until specified deadlines in late October and early November 2026 to join the class actions.

GlobeNewswire Inc.

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Unicycive Therapeutics for alleged securities fraud. The complaint alleges that the company made false statements about its manufacturing vendor's FDA compliance and failed to disclose material risks regarding regulatory approval delays for oxylanthanum carbonate. Investors who purchased shares between December 29, 2025 and June 29, 2026 may be eligible to join the lawsuit.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 20, 20251-for-10reverse split